Hepatitis C in Children-An Asia-Pacific Concise Perspective

Overview

Journal Pathogens

Date 2024 Oct 25

PMID 39452731

Authors

Lynette Goh

Winita Hardikar

Affiliations

Soon will be listed here.

Abstract

Since the discovery of hepatitis C virus (HCV) in 1989, we now have curative treatment options with direct-acting antiviral therapies. By increasing the rate of treatment and reducing transmission, the eradication of HCV is potentially achievable. Nonetheless, the feasibility and implementation of this goal remains challenging. This article sums up the approach to managing children with HCV in the Asia-Pacific region and lists some of the difficulties and complexities surrounding this issue.

References

Indolfi G, Gonzalez-Peralta R, Jonas M, Sayed M, Fischler B, Sokal E . ESPGHAN recommendations on treatment of chronic hepatitis C virus infection in adolescents and children including those living in resource-limited settings. J Pediatr Gastroenterol Nutr. 2024; 78(4):957-972. DOI: 10.1002/jpn3.12160. View

Razavi H, Elkhoury A, Elbasha E, Estes C, Pasini K, Poynard T . Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology. 2013; 57(6):2164-70. PMC: 3763475. DOI: 10.1002/hep.26218. View

Thursz M, Fontanet A . HCV transmission in industrialized countries and resource-constrained areas. Nat Rev Gastroenterol Hepatol. 2013; 11(1):28-35. DOI: 10.1038/nrgastro.2013.179. View

Mishra K, Shah A, Patel K, Ghosh K, Bharadva S . Seroprevalence of HBV, HCV and HIV-1 and Correlation with Molecular Markers among Multi-Transfused Thalassemia Patients in Western India. Mediterr J Hematol Infect Dis. 2020; 12(1):e2020038. PMC: 7340250. DOI: 10.4084/MJHID.2020.038. View

Lazarus J, Wiktor S, Colombo M, Thursz M . Micro-elimination - A path to global elimination of hepatitis C. J Hepatol. 2017; 67(4):665-666. DOI: 10.1016/j.jhep.2017.06.033. View

. EASL recommendations on treatment of hepatitis C: Final update of the series. J Hepatol. 2020; 73(5):1170-1218. DOI: 10.1016/j.jhep.2020.08.018. View

Jonas M, Rhee S, Kelly D, Del Valle-Segarra A, Feiterna-Sperling C, Gilmour S . Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Children With Chronic HCV: Part 2 of the DORA Study. Hepatology. 2021; 74(1):19-27. PMC: 8548879. DOI: 10.1002/hep.31841. View

Rodriguez-Baez N . Hepatitis C in Young Children: To Treat or Not to Treat - Is It Cost-Effective?. J Pediatr. 2020; 230:9-10. DOI: 10.1016/j.jpeds.2020.10.032. View

Gowda C, Smith S, Crim L, Moyer K, Sanchez P, Honegger J . Nucleic Acid Testing for Diagnosis of Perinatally Acquired Hepatitis C Virus Infection in Early Infancy. Clin Infect Dis. 2020; 73(9):e3340-e3346. PMC: 8563185. DOI: 10.1093/cid/ciaa949. View

10.

Aggarwal R, Chen Q, Goel A, Seguy N, Pendse R, Ayer T . Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India. PLoS One. 2017; 12(5):e0176503. PMC: 5435174. DOI: 10.1371/journal.pone.0176503. View

11.

Karaca C, Cakaloglu Y, Demir K, Ozdil S, Kaymakoglu S, Badur S . Risk factors for the transmission of hepatitis C virus infection in the Turkish population. Dig Dis Sci. 2006; 51(2):365-9. DOI: 10.1007/s10620-006-3139-6. View

12.

Rein D, Wittenborn J, Smith B, Liffmann D, Ward J . The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus. Clin Infect Dis. 2015; 61(2):157-68. PMC: 5759765. DOI: 10.1093/cid/civ220. View

13.

Bhatia H, Singh H, Grewal N, Natt N . Sofosbuvir: A novel treatment option for chronic hepatitis C infection. J Pharmacol Pharmacother. 2014; 5(4):278-84. PMC: 4231565. DOI: 10.4103/0976-500X.142464. View

14.

Nguyen J, Barritt 4th A, Jhaveri R . Cost Effectiveness of Early Treatment with Direct-Acting Antiviral Therapy in Adolescent Patients with Hepatitis C Virus Infection. J Pediatr. 2019; 207:90-96. DOI: 10.1016/j.jpeds.2018.12.012. View

15.

Jonas M, Romero R, Rosenthal P, Lin C, Verucchi G, Wen J . Sofosbuvir-velpatasvir in children 3-17 years old with hepatitis C virus infection. J Pediatr Gastroenterol Nutr. 2024; 78(6):1342-1354. DOI: 10.1002/jpn3.12045. View

16.

Stinco M, Bartolini E, Veronese P, Rubino C, Moriondo M, Ricci S . Epidemiology and Natural History of Childhood-Acquired Chronic Hepatitis C: A Single-Center Long-Term Prospective Study. J Pediatr Gastroenterol Nutr. 2022; 75(2):e2-e7. DOI: 10.1097/MPG.0000000000003481. View

17.

Jara P, Resti M, Hierro L, Giacchino R, Barbera C, Zancan L . Chronic hepatitis C virus infection in childhood: clinical patterns and evolution in 224 white children. Clin Infect Dis. 2003; 36(3):275-80. DOI: 10.1086/345908. View

18.

Modin L, Arshad A, Wilkes B, Benselin J, Lloyd C, Irving W . Epidemiology and natural history of hepatitis C virus infection among children and young people. J Hepatol. 2018; 70(3):371-378. DOI: 10.1016/j.jhep.2018.11.013. View

19.

Riaz M, Abbas M, Rasool G, Baig I, Mahmood Z, Munir N . Prevalence of transfusion-transmitted infections in multiple blood transfusion-dependent thalassemic patients in Asia: A systemic review. Int J Immunopathol Pharmacol. 2022; 36:3946320221096909. PMC: 9036341. DOI: 10.1177/03946320221096909. View

20.

Greenaway E, Haines A, Ling S, Krahn M . Treatment of Chronic Hepatitis C in Young Children Reduces Adverse Outcomes and Is Cost-Effective Compared with Deferring Treatment to Adulthood. J Pediatr. 2020; 230:38-45.e2. DOI: 10.1016/j.jpeds.2020.08.088. View